A multicentric, observational and prospective study analysing humoral response and safety of SARS-CoV-2 vaccines in Chronic kidney disease patients
Latest Information Update: 23 Nov 2021
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 23 Nov 2021 New trial record
- 12 Nov 2021 Interim Results published in the Nephrology Dialysis Transplantation